Proceedings of the National Academy of Sciences · 2017 · 62 citations · 25 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoveryMolecular OncologyDrug Resistance NetworksMolecular Tumor ProfilingNetwork PharmacologyOncology PharmacologySynthetic LethalityTargeted Cancer TherapyCancer Signaling Network AnalysisProtein Translation ControlSynergistic Combination ScreeningSynergistic Drug CombinationsSynergistic Drug InteractionsSynthetic Lethal Network AnalysisSynthetic Lethal ScreeningT-cell Acute Lymphoblastic Leukemia
gene is a major oncogenic driver and therapeutic target in T-cell acute lymphoblastic leukemia (T-ALL). However, inhibition of NOTCH signaling with γ-secretase inhibitors (GSIs) has shown limited antileukemic activity in clinical trials. Here we performed an expression-based virtual screening to identify highly active antileukemic drugs that synergize with NOTCH1 inhibition in T-ALL. Among these, withaferin A demonstrated the strongest cytotoxic and GSI-synergistic antileukemic effects in vitro and in vivo. Mechanistically, network perturbation analyses showed eIF2A-phosphorylation-mediated inhibition of protein translation as a critical mediator of the antileukemic effects of withaferin A and its interaction with NOTCH1 inhibition. Overall, these results support a role for anti-NOTCH1 therapies and protein translation inhibitor combinations in the treatment of T-ALL.
25
Activating Mutations of <i>NOTCH1</i> in Human T Cell Acute Lymphoblastic Leukemia
Andrew P. Weng, Adolfo A. Ferrando, Woojoong Lee et al. · Science · 2004 · 2.7K citations
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Teresa Palomero, Maria Luisa Sulis, Maria S. Cortina et al. · Nature Medicine · 2007 · 872 citations · Full text